Financial Gravity Companies’s Heron Therapeutics HRTX Stock Holding History

Financial Gravity Companies’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$3K	Buy	+98	New	+$2.69K	﹤0.01%	834

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Financial Gravity Companies's HRTX Position: Q4 2018 in Review

Financial Gravity Companies opened a new position in Heron Therapeutics (HRTX) in Q4 2018: 98 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #834 among its holdings.

176 funds tracked by Wall St. Rank hold HRTX as of Q4 2018.

Financial Gravity Companies held 98 shares of Heron Therapeutics worth $3K as of Q4 2018.
Heron Therapeutics was a new Financial Gravity Companies position in Q4 2018.
Heron Therapeutics made up ﹤0.01% of Financial Gravity Companies's portfolio in Q4 2018, its #834 holding.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2018.

Based on Financial Gravity Companies's 13F filing for Q4 2018, filed 4 Feb 2019.